Cornerstone Investment Partners LLC has initiated a significant new position in Thermo Fisher Scientific Inc. (TMO), purchasing over 85,000 shares. The investment, valued at approximately $41.39 million, aligns with recent portfolio adjustments by other major institutions like Vanguard and Norges Bank. This move follows the company's authorization of a massive $5 billion share buyback program, triggered by positive quarterly earnings results. Market analysts currently maintain a "Moderate Buy" rating on the stock, reflecting sustained institutional confidence in the healthcare giant. The average price target for TMO stands at $633.68, suggesting further upside potential from current levels. Despite some recent insider selling, the combination of large-scale buybacks and institutional backing provides a strong support level for the stock.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis